@article{ref1,
title="Depression and pegylated interferon-based hepatitis C treatment",
journal="International Journal of Interferon, Cytokine and Mediator Research",
year="2012",
author="Papafragkakis, H. and Rao, M.S. and Moehlen, M. and Dhillon, S. and Martin, P.",
volume="4",
number="1",
pages="25-35",
abstract="Interferon remains an essential component of treatment regimens for chronic hepatitis C infection. Mood disturbances, including depression, are relatively common in the hepatitis C virus-infected population and may worsen during hepatitis C treatment. Screening for depression prior to commencement of therapy is crucial and may improve treatment outcomes. Whether prophylactic antidepressant therapy should be initiated prior to therapy of hepatitis C virus infection with an interferon-based regimen remains unclear. We review the epidemiology, diagnosis, and management of depression before and during treatment of hepatitis C virus infection with interferon. © 2012 Papafragkakis et al.<p /><p>Language: en</p>",
language="en",
issn="1179-139X",
doi="10.2147/ijicmr.s28901",
url="http://dx.doi.org/10.2147/ijicmr.s28901"
}